ArticleScientific reports2025
A case-control study on the role of carbonic anhydrase autoantibodies in the pathogenesis and diagnosis of fibromyalgia.
Article in Scientific reports, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
To investigate the levels and diagnostic significance of carbonic anhydrase I (CAI) and II (CAII) autoantibodies and oxidative stress status in fibromyalgia syndrome (FMS) patients. A total of 59 FMS patients and 53 healthy controls were included. CAI and CAII autoantibody levels were measured using a manual ELISA protocol. Serum malondialdehyde (MDA), serum total oxidant status (TOS), serum total antioxidant status (TAS), and oxidative stress index (OSI) were also analyzed. The mean CAI and CAII autoantibody levels were significantly higher in the FMS group compared to the control group (p < 0.000 and p < 0.003, respectively). FMS patients had significantly higher MDA, TOS and OSI levels(p < 0.000 for all comparisons), and lower TAS levels compared to controls but no significant differences (p > 0,705). Elevated CAI and CAII autoantibodies and altered oxidative stress markers in FMS patients suggest autoimmune processes and oxidative stress involvement in the pathogenesis of FMS, providing new insights into potential diagnostic and therapeutic approaches.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.